Clinical trials: Cancer Progression
Cardiovascular Disease, Hypertension
Stop Atherosclerosis in Native Diabetics Study
Compared to standard treatment goals achieving lower targets for LDL cholesterol (bad cholesterol) and blood pressure in people with diabetes will slow the progression of atherosclerosis as measured by carotid artery thickness…
- Conditions
- Cardiovascular Disease, Hypertension, Hyperlipidemia, Diabetes
- Trial name
- SANDS (NCT00147251)
- Testing
- FDA approved drugs to treat blood pressure and cholesterol
- Where
- 4 sites in United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Cynthia West
Multiple Myeloma
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
The purpose of this study is determine Time-to-Progression with elotuzumab plus lenalidomide when elotuzumab is added to multiple myeloma participants with serologic relapse/progression while receiving lenalidomide maintenance…
- Trial name
- NCT03411031
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Hodgkin's Lymphoma
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
This multicenter, randomized, open-label, parallel-group study will evaluate the efficacy and safety of subcutaneously administered rituximab in comparison with observation only as maintenance therapy in participants with…
- Trial name
- MabCute (NCT01461928)
- Testing
- Chemotherapy (Induction Period), Rituximab
- Where
- 180 sites in Albania, Argentina and 22 more
- Volunteers
- 692 people
- Sponsor
- Hoffmann-La Roche
Epithelial Ovarian Cancer, Primary Peritoneal
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
- Trial name
- ATHENA (NCT03522246)
- Testing
- Rucaparib, Nivolumab
- Where
- 238 sites in United States, Australia and 22 more
- Volunteers
- 1,097 people
- Sponsor
- pharmaand GmbH
SARS-CoV-2
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Primary Objectives Phase 1 (Safety and Tolerability) Evaluate the safety and tolerability of REGN14256+imdevimab and REGN14256 monotherapy, as measured by treatment-emergent adverse events (TEAEs), injection-site reactions…
- Trial name
- NCT05081388
- Testing
- REGN14256, imdevimab, casirivimab + imdevimab
- Where
- 28 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
TXA and Corona Virus 2019 (COVID19) in Outpatients
A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.
- Trial name
- TCOutpatient (NCT04338074)
- Testing
- Tranexamic acid tablets
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Myopia
Controlling Myopia Progression With Soft Contact Lenses
This study is to investigate whether novel soft contact lens optical designs can slow myopia progression.
- Trial name
- NCT01787760
- Testing
- Test Soft Contact Lens B, Test Soft Contact Lens C, Active Comparator
- Where
- Hong Kong
- Volunteers
- 221 people
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Multiple Myeloma
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and…
- Trial name
- NCT01109004
- Testing
- Lenalidomide, lenalidomide, bortezomib and dexamethasone
- Where
- 54 sites in United States
- Volunteers
- 758 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
The standard approach to managing chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) is to wait until you have symptoms before treatment is given.
- Conditions
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
- Trial name
- NCT03207555
- Testing
- Ibrutinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
This is a study evaluating the safety and efficacy of the monoclonal antibody olaratumab plus mitoxantrone plus prednisone compared to mitoxantrone plus prednisone in metastatic castration-refractory prostate cancer following…
- Trial name
- NCT01204710
- Testing
- Olaratumab, Mitoxantrone, Prednisone
- Where
- 40 sites in Belgium, Czechia and 5 more
- Volunteers
- 123 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer
This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer.
- Trial name
- NCT00661778
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 14 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.
- Trial name
- NCT05577715
- Testing
- MORAb-202
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 31 people
- Sponsor
- Bristol-Myers Squibb
Pulmonary Disease, Chronic Obstructive
A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)
This is a pilot study to investigate the effect of danirixin hydrobromide 35 milligram (mg) tablets on lung function and health related quality of life (HRQoL) in subjects with mild to moderate airflow obstruction and a…
- Trial name
- NCT03170232
- Testing
- Danirixin 35 mg tablets, Metered dose inhaler (MDI) sensor device, Rescue medication
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.
- Trial name
- PERISCOPE (NCT00225277)
- Testing
- Pioglitazone, Glimepiride
- Where
- 79 sites in United States, Argentina and 2 more
- Volunteers
- 547 people
- Sponsor
- Takeda
Metastatic Breast Cancer, Advanced Breast Cancer
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
This study has the purpose to demonstrate clinical efficacy of the investigational new drug ertumaxomab in patients with human epidermal growth factor receptor-2 (HER-2/neu) overexpressing (3+ or 2+ with a positive Fluorescence…
- Trial name
- NCT00522457
- Testing
- ertumaxomab
- Where
- 5 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Neovii Biotech
COVID, COVID-19
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
This protocol will serve as a platform for assessing treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure.
- Conditions
- COVID, COVID-19, SARS-CoV-2, SARS (Severe Acute Respiratory Syndrome)
- Trial name
- NCT04546581
- Testing
- Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Remdesivir
- Where
- 39 sites in United States, Denmark and 5 more
- Volunteers
- 593 people
- Sponsor
- University of Minnesota
Cervical Cancer
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR).
- Trial name
- NCT04646005
- Testing
- Cemiplimab, ISA101b
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 113 people
- Sponsor
- Regeneron Pharmaceuticals
Cervical Cancer
Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer
RATIONALE: Diagnostic procedures, such as 64Cu-labeled diacetyl-bis[N4-methylthiosemicarbazone] (copper Cu 64-ATSM) PET/CT scans, may help doctors predict how patients will respond to treatment.
- Trial name
- ACRIN6682 (NCT00794339)
- Testing
- 64Cu-ATSM, FDG
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- American College of Radiology
Cardiovascular Diseases, Cardiovascular Abnormalities
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
The primary objective is to assess the effect of 2 dose levels of SNF472 (300 mg and 600 mg) compared to placebo on the progression of coronary artery calcium volume score over a 12-month (52 weeks) period in ESRD patients on HD
- Conditions
- Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease
- Trial name
- NCT02966028
- Testing
- SNF472
- Where
- 75 sites in United States, Spain and 1 more
- Volunteers
- 274 people
- Sponsor
- Sanifit Therapeutics S. A.
Neoplasms, Prostate
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
The purpose of this study is to examine the effect of dutasteride on the inhibition of low-risk, localized prostate cancer progression in men who would otherwise receive no active therapy (expectant management).
- Trial name
- NCT00363311
- Testing
- Dutasteride
- Where
- 82 sites in United States, Canada
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline